Research programme: Chlamydia vaccine - Roche/University of Massachusetts
Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator University of Massachusetts Amherst
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Chlamydial infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Chlamydial-infections in USA
- 26 Jun 2007 BioVeris Corporation has been acquired and merged into Roche
- 30 Apr 2007 Preclinical development is ongoing